Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


 

Stada Will Continue To Invest To Drive Growth

After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.

Strategy Deals

Coronavirus Spotlight


Coronavirus Spotlight

Remdesivir Compulsory Licensing Is A Dead End For Europe

In the wake of the revelation that the US has secured rights to almost all of Gilead’s remdesivir supplies through September 2020, compulsory licensing had been raised as a possible way for countries to procure versions of the COVID-19 treatment. However, Medicines for Europe has cautioned that the procedure will not be practical to apply in Europe.

Coronavirus COVID-19 Intellectual Property

IQVIA Backs Global Generics & Biosimilars Awards 2020

IQVIA has joined the Global Generics & Biosimilars Awards 2020 as headline sponsor, while West AccelTRA will lend its backing to the awards as a category sponsor. The awards, which are free to enter and attend, will take place in October 2020 in Milan, Italy.

Generic Drugs Biosimilars Value-Added Medicines

Advanz Seeks To Build On European Platform

Advanz Pharma recently struck two major deals that have expanded its presence in Europe and bolstered its portfolio. In an exclusive interview with Generics Bulletin, CEO Graeme Duncan explains how the firm plans to build on these moves to make the most of its enhanced platform.

Strategy Deals M & A
 

Commercial Explore this Topic

Set Alert for Commercial

Stada Will Continue To Invest To Drive Growth

After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.

Strategy Deals

Hikma Set To Buy Back £295m In Shares

Boehringer Ingelheim, which holds a 16.4% share of Hikma along with voting rights, is ready to exit the company altogether as Hikma decides to buy back £295m worth of shares. Hikma has invited new investors, expressing confidence in its future plans.

Deals Strategy

WHO’s Cooke To Take Lead At EMA

Currently serving at the WHO, Emer Cooke is set to return to the EMA later this year in the role of executive director. She will have to tackle challenges posed by Brexit, COVID-19 and recent agency restructuring.

Appointments Regulation

Carlyle Pays Almost $500m For A Fifth Of Piramal Pharma

Private equity group Carlyle has acquired 20% of Piramal’s pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.

Deals India

BGMA Backs UK COVID-19 Recovery Roadmap

Putting forward a roadmap for recovery from COVID-19, the ‘Life Sciences COVID-19 Response Group,’ established in March 2020, has insisted that positive factors introduced during the COVID-19 pandemic should be enhanced and retained.

Coronavirus COVID-19 Policy & Regulation

Perrigo Bolsters US Generics Ahead Of Separation Plans

Perrigo has expanded its agreement with Sol-Gel Technologies to cover ten products, shortly after warning that plans to separate the firm’s Prescription Pharmaceuticals US generics unit “in the short term” would likely “destroy shareholder value.”

Deals Generic Drugs
See All

Policy & Regulation Explore this Topic

Set Alert for Policy and Regulation

WHO’s Cooke To Take Lead At EMA

Currently serving at the WHO, Emer Cooke is set to return to the EMA later this year in the role of executive director. She will have to tackle challenges posed by Brexit, COVID-19 and recent agency restructuring.

Appointments Regulation

EU Sees Drug Shortage Risk From COVID-19 Second Wave

A second wave of COVID-19 infection later this year would put even greater pressure on drugs used in patients hospitalized with serious respiratory problems, a new report warns.

Europe Coronavirus COVID-19

Celltrion Extends Remsima SC Indications

Celltrion has received a positive opinion from the CHMP for five additional indications for its Remsima SC biosimilar, expanding the scope of the subcutaneous infliximab product that was launched earlier this year.

Biosimilars Europe

Pfenex And Alvogen Forsteo Biosimilars Primed For EU Market

Shortly after announcing the launch of Bonsity (teriparatide) in the US, Pfenex and Alvogen have picked up positive opinions from the EMA’s CHMP for their teriparatide biosimilar. However, Accord Healthcare has withdrawn its own application following concerns raised by the agency.

Biosimilars Regulation

Samsung Bioepis Bevacizumab Nod Sets Stage For EU Throwdown

Samsung Bioepis has received a pan-European endorsement from the CHMP for its Aybintio bevacizumab biosimilar. The nod follows two previous European Avastin biosimilar approvals, with market formation believed to be imminent.

Biosimilars Regulation

UK-US Trade Deal Benefits From Biologic Exclusivity ‘Commitment’

The US Trade Representative Robert Lighthizer has intimated that a controversial provision requiring 10 years of biologic data exclusivity would not be contained in a proposed free trade agreement with the UK, as it seeks partners following its exit from the EU.

Trade Regulation
See All

Generic Drugs Explore this Topic

Set Alert for Generic Drugs

Stada Will Continue To Invest To Drive Growth

After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.

Strategy Deals

Remdesivir Compulsory Licensing Is A Dead End For Europe

In the wake of the revelation that the US has secured rights to almost all of Gilead’s remdesivir supplies through September 2020, compulsory licensing had been raised as a possible way for countries to procure versions of the COVID-19 treatment. However, Medicines for Europe has cautioned that the procedure will not be practical to apply in Europe.

Coronavirus COVID-19 Intellectual Property

Argentina's CILFA Joins IGBA

Argentina’s off-patent industry association, CILFA, has joined global body the IGBA as an associate member.

Argentina International
See All

Biosimilars Explore this Topic

Set Alert for Biosimilars

Stada Will Continue To Invest To Drive Growth

After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.

Strategy Deals

Samsung Bioepis Added To Avastin Biosimilar Litigants

Samsung Bioepis is the latest company to stare down a lawsuit from Genentech over Avastin patents in the US. The Korean firm is aiming to be amongst the early biosimilar movers, after the market formed a year ago.

Biosimilars Legal Issues

AAM Welcomes Biosimilar Access Bill

A US bill aimed at promoting biosimilars by encouraging greater prescribing rates and creating a shared savings demonstration program for biosimilars has been warmly welcomed by the AAM.

Legislation Policy & Regulation
See All

Value-Added Medicines Explore this Topic

Set Alert for Value-Added Medicines

Argentina's CILFA Joins IGBA

Argentina’s off-patent industry association, CILFA, has joined global body the IGBA as an associate member.

Argentina International

Hyloris Sets Out IPO Terms

Value-added medicines specialist Hyloris Pharmaceuticals has set out the financial terms for its IPO, aimed at providing funds to pursue US 505(b)(2) opportunities.

Strategy Value-Added Medicines

Mylan Ups Investment In Mapi’s Monthly Glatiramer

Mylan has invested a further $20m in a monthly glatiramer acetate depot product being developed by partner Mapi for submission via the 505(b)(2) route in the US.

Deals Value-Added Medicines
See All
UsernamePublicRestriction

Register